Ingenia Therapeutics

Based in Watertown, Massachusetts, Ingenia Therapeutics is a biotechnology company focused on developing therapeutic antibodies to treat diseases caused by dysfunctional microvessels. The company was founded in 2018 by Sangyeul Han, who currently serves as President and Chief Executive Officer. Dr. Han's extensive background in molecular and cell biology, particularly in vascular biology and therapeutic antibody development, is central to the company's scientific direction. His experience includes leading antibody technology groups at Cell Signaling Technology and a therapeutic antibody development project at Samsung Advanced Institute of Technology, following post-doctoral training at Massachusetts General Hospital and Harvard Medical School.

Ingenia Therapeutics operates in the biopharmaceutical market, specifically targeting ophthalmic and systemic diseases characterized by inflamed and leaky blood vessels. The company's business model centers on the discovery and development of its antibody candidates, with a strategy that involves forming research and development partnerships with larger pharmaceutical companies to advance its products through to human proof-of-concept studies. Since its inception, Ingenia has secured $12 million in total funding over two Series A rounds, with the most recent being $5 million raised in June 2024.

The core of the company's offering is its proprietary technology platform for discovering and developing novel antibodies. This platform targets specific proteins and modulates endothelial and immune signaling pathways to restore the health and function of damaged microvessels. The company has built a pipeline of therapeutic candidates, with its initial focus on ophthalmic conditions like diabetic retinopathy. Its lead product candidate, IGT-427, is a monoclonal antibody in the preclinical stage, aimed at treating diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Ingenia has established a collaboration with Nona Biosciences to advance its programs.

Keywords: Ingenia Therapeutics, therapeutic antibodies, microvessel dysfunction, endothelial biology, ophthalmic diseases, systemic vasculitis, Sangyeul Han, antibody development, biopharmaceutical, drug discovery, IGT-427, diabetic retinopathy, monoclonal antibody, vascular diseases, preclinical stage, Series A funding, Watertown biotech, capillary disease, endothelial signaling, immune signaling pathways